RENISSE TRECIA TRILLANA: Open Payments
NPI 1073978359 · DENVER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,098 in 66 payments from 12 companies in 2025. Trend: 2023 $567 · 2024 $562 · 2025 $2,098
Food & beverage: $1,999Education: $99
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 12 | $730 |
| Madrigal Pharmaceuticals | 9 | $404 |
| ABBVIE INC. | 14 | $283 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $195 |
| PFIZER INC. | 10 | $156 |
| Celltrion USA Inc. | 4 | $84 |
| Ardelyx, Inc. | 2 | $55 |
| Aimmune Therapeutics, Inc. | 2 | $52 |
| Regeneron Healthcare Solutions, Inc. | 2 | $51 |
| GENZYME CORPORATION | 2 | $48 |
Products named: TREMFYA, REZDIFFRA, ENTYVIO, RINVOQ, XELJANZ, DUPIXENT, VEGZELMA, IBSRELA.
Industry payments across CO — which companies pay providers there.
